The vaccine developed by the French laboratory Sanofi in partnership with the American Translate Bio, will not be available in 2021, said the CEO of Sanofi in an interview with the Journal du dimanche. Clinical trials of this vaccine are expected to begin in the first quarter of the year.
This is a new setback for French research in the fight against Covid-19 . The vaccine developed by Sanofi in partnership with the American Translate Bio from messenger RNA technology will not be ready this year, said Paul Hudson, the general manager of the French pharmaceutical group in an interview with the Journal du Dimanche .
Clinical trials of this vaccine, which is based on the same technology as the Pfizer-BioNTech and Moderna vaccines already on the market, are due to begin this quarter.
In December 2020, Sanofi said it was targeting a potential authorization for this vaccine in the second half of 2021 at the earliest, following positive preclinical trials.
A vaccine that “could prove useful later”
“This vaccine will not be ready this year, but it could prove useful later, especially if the fight against the variants were to continue,” Sanofi general manager Paul Hudson told JDD, without giving any further details.
Sanofi had already announced in December that another vaccine candidate that it is developing with the British laboratory GlaxoSmithKline would not be available before the fourth quarter of 2021 when provisional data from a clinical trial showed unsatisfactory results for the most elderly.
Last month, Sanofi agreed to participate in the vial of millions of doses of the Pfizer-BioNTech vaccine from July 2021.